6/28/23, 12:07 AM CHARM-Preserved Pathway Feedback Search Clinical Topics Home Studies CHARM Preserved CHARM Preserved Disease Heart failure Trial question What is the role of candesartan in patients with chronic HF and preserved left-ventricular ejection fraction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 40.0% female N = 3023 60.0% male 3023 patients (1212 female, 1811 male) Inclusion criteria: patients with chronic HF and preserved left-ventricular ejection fraction Key exclusion criteria: life-threatening adverse event; known bilateral renal artery stenosis; current symptomatic hypotension; persistent systolic or diastolic hypertension; stroke, acute myocardial infarction, or open heart surgery within the last 4 weeks; or previous heart transplant or heart transplant expected to be performed within the next 6 months Interventions N=1514 candesartan (target dose 32 mg once daily) N=1509 placebo (matching placebo daily) Primary outcome Cardiovascular death or admission to hospital for CHF 24 24 0 % 22 https://web.pathway.md/studies/recUc3ap5LC2KVloG 1/2 6/28/23, 12:07 AM 24.0 % CHARM-Preserved Pathway 22 18.0 % 12.0 % 6.0 % Borderline significant decrease 0.0 % Candesartan Placebo Borderline significant decrease in cardiovascular death or admission to hospital for CHF (22% vs. 24%; aHR 0.86, 95% CI 0.74 to 1) Secondary outcomes Significant decrease in nonfatal myocardial infarction and nonfatal stroke (26% vs. 28%; aHR 0.86, 95% CI 0.75 to 0.99) Significant decrease in hospital admission for chronic HF (15.9% vs. 18.3%; aHR 0.84, 95% CI 0.7 to 1) No significant difference in cardiovascular death (11.2% vs. 11.3%; aHR 0.95, 95% CI 0.76 to 1.18) Safety outcomes Significant difference in drug discontinuation due to adverse event or laboratory abnormality (17.8% vs. 13.5%). Conclusion In patients with chronic HF and preserved left-ventricular ejection fraction, candesartan was superior to placebo with respect to cardiovascular death or admission to hospital for CHF. Reference Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362(9386):777-81. Open reference URL https://web.pathway.md/studies/recUc3ap5LC2KVloG 2/2